Stocks

BridgeBio Oncology Therapeutics, Inc.

BBOTNASDAQUSDHealthcare

About BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Ticker
BBOT
Trading on
NASDAQ
ISIN
-
Industry
Biotechnology
Sector
Healthcare
CEO
-
Headquarters
256 East Grand Avenue, South San Francisco, CA, United States, 94080
Employees
92
Website
https://bbotx.com

Metrics

Market cap$149M
P/E ratio3.51
EPS$0.53
Dividend Yield0.00%
Beta0.86
Forward P/E ratio0
EBIDTA$-187M
Ex dividend date-

Analyst Insights & forecasts

Buy100%
Hold0%
Sell0%

Based on information from 12 analysts.

Average price target$20.91

Earnings per share (EPS) forecast

Q4 • 25Q1 • 26Q2 • 26
Actual-$0.49-$526.11-$0.71
Expected-$0.66-$0.51-$0.55
Surprise25.76%-102,777.32%-29.09%
BeatMissedCurrent

Financial Performance

Q2 • 26Q3 • 26QoQ growth
Revenue$0M$0MNaN%
Net income$-56.5M$-34.2M-39.46%
Profit margin-∞%-∞%NaN%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

FAQs

01How much is a BridgeBio Oncology Therapeutics, Inc. share?

BridgeBio Oncology Therapeutics, Inc. shares are currently traded for undefined per share.

02How many shares does BridgeBio Oncology Therapeutics, Inc. have?

BridgeBio Oncology Therapeutics, Inc. currently has 80.3M shares.

03Does BridgeBio Oncology Therapeutics, Inc. pay dividends?

No, BridgeBio Oncology Therapeutics, Inc. doesn't pay dividends.

04What is BridgeBio Oncology Therapeutics, Inc. 52 week high?

BridgeBio Oncology Therapeutics, Inc. 52 week high is $14.87.

05What is BridgeBio Oncology Therapeutics, Inc. 52 week low?

BridgeBio Oncology Therapeutics, Inc. 52 week low is $1.79.

06What is the 200-day moving average of BridgeBio Oncology Therapeutics, Inc.?

BridgeBio Oncology Therapeutics, Inc. 200-day moving average is $7.49.

07Who is BridgeBio Oncology Therapeutics, Inc. CEO?

The CEO of BridgeBio Oncology Therapeutics, Inc. is -.

08How many employees BridgeBio Oncology Therapeutics, Inc. has?

BridgeBio Oncology Therapeutics, Inc. has 92 employees.

09What is the market cap of BridgeBio Oncology Therapeutics, Inc.?

The market cap of BridgeBio Oncology Therapeutics, Inc. is $149M.

10What is the P/E of BridgeBio Oncology Therapeutics, Inc.?

The current P/E of BridgeBio Oncology Therapeutics, Inc. is 3.51.

11What is the EPS of BridgeBio Oncology Therapeutics, Inc.?

The EPS of BridgeBio Oncology Therapeutics, Inc. is $0.53.

12What is the PEG Ratio of BridgeBio Oncology Therapeutics, Inc.?

The PEG Ratio of BridgeBio Oncology Therapeutics, Inc. is null.

13What do analysts say about BridgeBio Oncology Therapeutics, Inc.?

According to the analysts BridgeBio Oncology Therapeutics, Inc. is considered a buy.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.